Is MGM-15 (dihydro-7-hydroxymitragynine) Legal in Indiana? (2026)

Instrument

Synthetic drug; Schedule I; Controlled substance analog; board determinations

Source

https://iga.in.gov/ic/2026/Title_35.html

Retrieved

2026-10-29

Fingerprint

88b34e95cb1e088e

IC 35-31.5-2-321
"Synthetic drug"
     
Sec. 321. "Synthetic drug" means the following:
(1) A substance containing one (1) or more of the following
chemical compounds, including an analog of the compound:
JWH-015 ((2-Methyl-1-propyl-1H-
indol-3-yl)-1-naphthalenylmethanone).
JWH-018 (1-pentyl-3-(1-naphthoyl)indole).
JWH-019 (1-hexyl-3-(naphthalen-1-oyl)indole).
JWH-073 (naphthalen-1-yl-(1-butylindol-3-yl)methanone).
JWH-081 (4-methoxynaphthalen- 1-yl- (1-pentylindol-
3-yl)methanone).
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
JWH-200 ((1-(2-morpholin-4-ylethyl)indol-3-yl)-
naphthalen-1-yl-methanone).
JWH-250 (1-pentyl-3-(2-methoxyphenylacetyl)indole).
JWH-251 (1-pentyl-3-(2-methylphenylacetyl)indole).
JWH-398 (1-pentyl-3-(4-chloro-1-naphthoyl)indole).
HU-210 ((6aR,10aR)- 9-(Hydroxymethyl)- 6,6-dimethyl-
3-(2-methyloctan-2-yl)-
6a,7,10,10a-tetrahydrobenzo [c]chromen- 1-ol).
HU-211 ((6aS,10aS)-9-(Hydroxymethyl)- 6,6-dimethyl-
3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo
[c]chromen-1-ol).
HU-308 ([(1R,2R,5R)-2-[2,6-dimethoxy-4- (2-methyloctan-
2-yl)phenyl]-
7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol).
HU-331 (3-hydroxy-2- [(1R,6R)-3-methyl-6-
(1-methylethenyl)-2 -cyclohexen-1-yl]-5
-pentyl-2,5-cyclohexadiene-1,4-dione).
CP 55,940
(2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]- 5-
(2-methyloctan-2-yl)phenol).
CP 47,497 (2-[(1R,3S)-3-hydroxycyclohexyl]- 5-
(2-methyloctan-2-yl)phenol) and its homologues, or
2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)
phenol), where side chain n=5, and homologues where side
chain n=4, 6, or 7.
WIN 55212-2
((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
pyrrolo [1,2,3-de)- 1,4- benzoxazin-
6-yl]-1-napthalenylmethanone).
RCS-4 ((4-methoxyphenyl)
(1-pentyl-1H-indol-3-yl)methanone).
RCS-8 (1-(1-(2-cyclohexylethyl)-1H-
indol-3-yl)-2-(2-methoxyphenyl)ethanone).
4-Methylmethcathinone. Other name: mephedrone.
3,4-Methylenedioxymethcathinone. Other name: methylone.
Fluoromethcathinone.
4-Methoxymethcathinone. Other name: methedrone.
4-Ethylmethcathinone (4-EMC).
Methylenedioxypyrovalerone. Other name: MDPV.
JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole.
JWH-098, or
1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole.
JWH-164, or
1-pentyl-3-(7-methoxy-1-naphthoyl)indole.
JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole.
JWH-201, or
1-pentyl-3-(4-methoxyphenylacetyl)indole.
JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole.
AM-694, or
1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole.
CP 50,556-1, or
[(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpe
ntan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1
-yl] acetate.
Dimethylheptylpyran, or DMHP.
4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP.
6-APB [6-(2-aminopropyl)benzofuran].
7-hydroxymitragynine.
α-PPP [α-pyrrolidinopropiophenone].
α-PVP (desmethylpyrovalerone).
AM-251.
AM-1241.
AM-2201.
AM-2233.
Buphedrone (α-methylamino-butyrophenone (MABP)).
Butylone.
CP-47,497-C7.
CP-47,497-C8.
Desoxypipradol.
Ethylone.
Eutylone.
Flephedrone.
JWH-011.
JWH-020.
JWH-022.
JWH-030.
JWH-182.
JWH-302.
MDAI [5,6-methylenedioxy-2-aminoindane].
Mitragynine.
Naphyrone.
Pentedrone.
Pentylone.
A796,260 [1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-
(2,2,3,3-tetramethylcyclopropyl)methanone].
AB-001[(1s,3s)-admantan-1-yl)
(1-pentyl-1H-indol-3-yl)methanone] or [1-Pentyl-3-
(1-adamantoyl)indole].
AM-356 [Methanandamide].
AM 1248 [1-[(1-methyl-2- piperidinyl) methyl]- 1H-indol-3-yl]
tricyclo[3.3.1.13,7] dec-1-yl-methanone]or
[(1-[(N-methylpiperindin-2-yl)
Methyl]-3-(Adamant-1-oyl)indole)].
AM 2233 Azepane isomer [(2-iodophenyl)
(1-(1-methylazepan-3-yl)- 1H-indol-3-yl)methanone].
CB-13 [1-Naphthalenyl
[4-(pentyoxy)- 1-naphthalenyl]methanone].
UR-144 [(1-pentyl-1H-indol-3-yl)
(2,2,3,3-tetramethylcyclopropyl)-methanone].
URB 597 [(3'-(aminocarbonyl) [1,1'-biphenyl]-3-yl)-
cyclohexylcarbamate].
URB602 [[1,1'-biphenyl]- 3-yl-carbamic acid, cyclohexyl ester].
URB 754 [6-methyl-2-[(4-methylphenyl)
amino]-1-benzoxazin-4-one].
XLR-11 or 5-fluoro UR-144
(1-(5-fluoropentyl)-1H-indol-3-yl)
(2,2,3,3-tetramethylcyclopropyl)methanone].
AKB48 (Other names include:
N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide;
1-pentyl-N-tricyclo[3.3.1.13.7]dec-1-yl-1H-indazole-3-
carboxamide).
25I-NBOMe (Other names include:
4-Iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-
benzeneethanamine);
2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
methyl]ethanamine).
2C-C-NBOMe (Other names include: 25C-NBOMe;
2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
methyl]ethanamine;
2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)
phenethylamine).
2NE-1 (Other names include: 1-Pentyl-3-
(1-adamantylamido)indole).
STS-135 (Other names include:
N-Adamantyl-1-fluoropentylindole-3- carboxamide
(1-5-fluoropentyl)-N-tricyclo[3.3.1.13.7]dec-1-yl-1H-
indole-3-carboxamide).
PB-22 (Other names include: 1-Pentyl-8-quinolinlyl
ester-1H-indole-2-carboxylic acid).
5-Fluoro-PB-22 (Other names include:
1-(5-Fluropentyl)-8-quinolinyl ester1H-indole-3-carboxylic
acid).
Benocyclidine (Other names include: BCP, BTCP, and
Benzothiophenylcyclohexylpiperidine).
25B-NBOMe (Other names include: 2C-B-NBOMe and
4-Bromo-2,
5-dimenthoxy-N-[(2-Methozyphenyl)methyl]
benzeneethanamine).
APB (Other names include: (2-Aminopropyl) Benzofuran).
AB-PINACA
(N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
indazole-3-carboxamide.
AB-FUBINACA
(N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-
1H-indazole-3-carboxamide).
ADB-PINACA
(N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
indaole-3-carboxamide).
Fluoro ADBICA (N-(1-Amino-3,3-
dimethyl-1-oxobutan-2-yl)-(fluoropentyl)-1H-indole-3-
carboxamide).
APDB (Other names include: -EMA, -Desoxy-MDA, and
(2-Aminopropyl)-2,3-
dihydrobenzofuran).
THJ-2201 (Other names include: AM2201 indazole analog,
Fluoropentyl-JWH-018 indazole, and 5-Fluoro-THJ-018).
AM 2201 benzimidazole analog (Other names include:
FUBIMINA, FTHJ, and (1-(5-fluoropentyl)-1H-
benzo[d]imidazol-2-yl)(naphthalene-1-yl)methanone).
MN-25 (Other names include: 7-methoxy-1-
[2-(4-morpholinyl)ethyl]-N-[1S, 2S, 4R)-1,3,3-
trimethylbicyclo[2.2.1]hept-2-yl]-1H-indole-3-carboxamide and
UR-12).
FUB-PB-22 (Other names include:
Quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate).
FUD-PB-22 (Other names include:
Naphthalen-1-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate).
5-Fluoro-AB-PINACA (Other names include: AB-PINACA
5-fluoro analog and N-(1-amino-3-methyl1-
oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-
carboxaminde).
4-MePPP (Other names include:
4-methyl-alpha-pyrrolidinopropiophenone).
alpha-PBP (Other names include:
Alpha-pyrrolidinobutiophenone).
AB-CHMINACA (Other names include:
(N-[1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethy
l)-1H-indazole-3-carboxamide).
Mexedrone
(3-methoxy-2-(methylamino)-1-(p-tolyl)propan-1-one).
MT-45,
(1-cyclohexyl-4-(1,2-diphenylethyl)piperazine).
methyl 2-(1-(5-fluoropentyl)- 1H-indazole-3- carboxamido)
-3,3-dimethylbutanoate [5F-ADB; 5F-MDMB-PINACA].
methyl 2-(1-(5-fluoropentyl)-1H- indazole-3-
carboxamido)-3-methylbutanoate [5F-AMB].
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl) -1-(4-fluorobenzyl)-
1H-indazole-3-carboxamide [ADB-FUBINACA].
N-(adamantan-1-yl)-1-(5-fluoropentyl)- 1H-indazole-3-
carboxamide [5F-APINACA, 5F-AKB48].
methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-
carboxamido)-3,3-dimethylbutanoate [MDMB-CHMICA,
MMB-CHMINACA].
methyl 2-(1-(4-fluorobenzyl)- 1H-indazole-3-carboxamido)-
3,3-dimethylbutanoate [MDMB-FUBINACA].
N-(1-amino-3,3-dimethyl-1 -oxobutan-2-yl)-1-
(cyclohexylmethyl)- 1H-indazole-3-carboxamide
[MAB-CHMINACA and ADB-CHMINACA].
Methyl 2-(1-(4-fluorobenzyl)-1H-indazole- 3-carboxamido)-
3-methylbutanoate [FUB-AMB, MMB-FUBINACA,
AMB-FUBINACA].
3,4-dichloro-N-[(1dimethylamino)cyclohexylme
thyl]benzamide) [AH7921].
Naphthalen-1-yl 1-(5-fluoropentyl)-1 H-indole-3-carboxylate
(trivial name: NM2201; CBL2201)
1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1
H-indazole-3-carboxamide (trivial name:
4-CN-CUMYL-BUTINACA; 4-cyano-CUMYL-BUTINA CA;
4-CN-CUMYL BINACA; CUMYL-4CN-BINACA; SGT-78).
methyl 2-(1-(cyclohexylmethyl)-1
H-indole-3-carboxamido)-3-methylbutanoate (trivial names:
MMB-CHMICA, AMB-CHMICA).
1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1
H-pyrrolo[2,3-b]pyridine-3-carboxamide (trivial name:
5F-CUMYL-P7AICA).
N-1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-p entanone
(N-ethylpentylone, ephylone).
Synthetic cathinone, 1-(1,3-benzodioxol-5-yl)-2- (ethylamino)-
pentan-1-one (N-ethylpentylone, ephylone) and its optical,
positional, and geometric isomers, salts, and salts of isomers.
ethyl
2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-
dimethylbutanoate (trivial name: 5F-EDMB-PINACA).
methyl 2-(1-(5- fluoropentyl)-1H-indole-3-
carboxamido)-3,3-dimethylbutanoate (trivial name:
5F-MDMB-PICA).
N- (adamantan- 1-yl)- 1-(4-fluorobenzyl)-
1H-indazole-3-carboxamide (trivial names: FUB-AKB48;
FUB-APINACA; AKB48 N- (4-FLUOROBENZYL)).
1-(5- fluoropentyl)-N-(2-phenylpropan-2-yl)-
1H-indazole-3-carboxamide (trivial names:
5F-CUMYL-PINACA; SGT-25).
(1-(4-fluorobenzyl)-1H-indol-3-
yl)(2,2,3,3-tetramethylcyclopropyl) methanone (trivial name:
FUB-144).
4F-MDMB-BINACA.
N-ethylhexedrone (2-(ethylamino)-1-phenylhexan-1-one).
alpha-pyrrolidinohexanophenone
(1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one.
alpha-pyrrolidinohexiophenone; trivial name: a-PHP.
4'-methyl-alpha-pyrrolidinohexiophenone
(1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one.
4-methyl-alphaethylaminopentiophenone
(2-(ethylamino)-1-(4-methylphenyl)pentan-1-one; trivial name:
4–MEAP.
4'-methyl-alphapyrrolidinohexanophenone; trivial name:
MPHP.
alphapyrrolidinoheptaphenone
(1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one; trivial name: PV8.
4'-chloro-alphapyrrolidinovalerophenone (1-(4-
chlorophenyl)-2-(pyrrolidin-1- yl)pentan-1-one.
4'-chloro-alphapyrrolidinopentiophenone; trivial name:
4-chloro-a-PVP.
MDMB-4en-PINACA; Methyl
3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H[1]indazole-3-carboxamido)butanoate.
4F-MDMB-BICA; 4-fluoro MDMB-BICA;
4F-MDMB-BUTICA; Methyl
2-[[1-(4-fluorobutyl)indole-3-carbonyl]amino]-3,
3-dimethyl-butanoate. Other name: 4-fluoro MDMB-BICA.
(2) Any compound structurally derived from
3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by
substitution at the nitrogen atom of the indole ring by alkyl,
haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
or not further substituted in the indole ring to any extent and
whether or not substituted in the naphthyl ring to any extent.
(3) Any compound structurally derived from 3-(1-naphthoyl)
pyrrole by substitution at the nitrogen atom of the pyrrole ring by
alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl,
1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl
group, whether or not further substituted in the pyrrole ring to any
extent and whether or not substituted in the naphthyl ring to any
extent.
(4) Any compound structurally derived from
1-(1-naphthylmethyl)indene by substitution at the 3-position of
the indene ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
or not further substituted in the indene ring to any extent and
whether or not substituted in the naphthyl ring to any extent.
(5) Any compound structurally derived from 3-phenylacetylindole
by substitution at the nitrogen atom of the indole ring with alkyl,
haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
or not further substituted in the indole ring to any extent and
whether or not substituted in the phenyl ring to any extent.
(6) Any compound structurally derived from
2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position
of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
or not substituted in the cyclohexyl ring to any extent.
(7) Any compound containing a 3-(benzoyl)indole structure with
substitution at the nitrogen atom of the indole ring by alkyl,
haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
or not further substituted in the indole ring to any extent and
whether or not substituted in the phenyl ring to any extent.
(8) Any compound, except bupropion or a compound listed under
a different schedule, structurally derived from
2-aminopropan-1-one by substitution at the 1-position with either
phenyl, naphthyl, or thiophene ring systems, whether or not the
compound is further modified:
(A) by substitution in the ring system to any extent with alkyl,
alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide
substituents, whether or not further substituted in the ring
system by one or more other univalent substituents;
(B) by substitution at the 3-position with an acyclic alkyl
substituent;
(C) by substitution at the 2-amino nitrogen atom with alkyl,
dialkyl, benzyl, or methoxybenzyl groups; or
(D) by inclusion of the 2-amino nitrogen atom in a cyclic
structure.
(9) Any compound structurally derived from 3-tetramethyl
cyclopropanoylindole with substitution at the nitrogen atom of the
indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl) ethyl,
1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-methyl-3-
morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
or not further substituted in the indole ring to any extent and
whether or not substituted in the tetramethylcyclopropyl ring to
any extent.
(10) Any compound containing a N-(1-adamantyl)-
1H-indazole-3-carboxamide structure with substitution at the
nitrogen atom of the indazole ring by an alkyl, haloalkyl,
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
1-(N-methyl-2-pyrrolidinyl)methyl,
1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl
group, whether or not further substituted at the nitrogen atom of
the carboxamide to any extent, whether or not further substituted
in the indazole ring to any extent, and whether or not further
substituted on the adamantyl ring system to any extent. An
example of this structural class includes AKB48.
(11) Any compound containing a N-(1-adamantyl)-
1H-indole-3-carboxamide structure with substitution at the
nitrogen atom of the indole ring by an alkyl, haloalkyl,
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
1-(N-methyl-2-pyrrolidinyl)methyl,
1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl
group, whether or not further substituted at the nitrogen atom of
the carboxamide to any extent, whether or not further substituted
in the indole ring to any extent, and whether or not further
substituted on the adamantyl ring system to any extent. An
example of this structural class includes STS-135.
(12) Any compound containing a 3-(1-adamantoyl)indole
structure with substitution at the nitrogen atom of the indole ring
by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl,
1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl
group, whether or not further substituted on the adamantyl ring
system to any extent. An example of this structural class includes
AM-1248.
(13) Any compound determined to be a synthetic drug by rule
adopted under
IC 25-26-13-4.1
.
As added by P.L.114-2012, SEC.67. Amended by P.L.196-2013,
SEC.16; P.L.168-2016, SEC.10; P.L.8-2017, SEC.1; P.L.89-2018,
SEC.1; P.L.119-2019, SEC.2; P.L.61-2020, SEC.2; P.L.48-2023,
SEC.2; P.L.186-2025, SEC.226.

(g) Synthetic drugs as defined in
IC 35-31.5-2-321
.

IC 35-48-1.1-8
“Controlled substance analog”
     
Sec. 8. (a) “Controlled substance analog” means a
substance that, due to its chemical structure and potential for abuse or
misuse, meets the following criteria:
(1) The substance is substantially similar to a controlled substance
classified under
IC 35-48-2
.
(2) The substance has a narcotic, stimulant, depressant, or
hallucinogenic effect on the central nervous system or is
represented or intended to have a narcotic, stimulant, depressant,
or hallucinogenic effect on the central nervous system
substantially similar to or greater than that of a controlled
substance classified under
IC 35-48-2
.
     
(b) The definition set forth in subsection (a) does not include:
(1) a controlled substance;
(2) a legend drug;
(3) a substance for which there is an approved new drug
application;
(4) any compound, mixture, or preparation that contains any
controlled substance, that is not for administration to a human
being or an animal, and that is packaged in a form or
concentration, or with adulterants or denaturants, such that as
packaged it does not present any significant potential for abuse;
(5) a substance to which an investigational exemption applies
under Section 505 of the federal Food, Drug and Cosmetic Act
(chapter 675, 52 Stat. 1052 (21 U.S.C. 355)), but only to the
extent that conduct with respect to the substance is pursuant to the
exemption; or
(6) low THC hemp extract.
     
(c) For purposes of subsection (a), “substantially similar”, as it
applies to the chemical structure of a substance, means that the
chemical structure of the substance, when compared to the structure of
a controlled substance, has a single difference in the structural formula
that substitutes one (1) atom or functional group for another, including:
(1) one (1) halogen for another halogen;
(2) one (1) hydrogen for a halogen;
(3) one (1) halogen for a hydrogen; or
(4) an alkyl group added or deleted:
(A) as a side chain to or from a molecule; or
(B) from a side chain of a molecule.
As added by P.L.186-2025, SEC.249.

(d) If any substance is designated or rescheduled to a more
restrictive schedule as a controlled substance under federal law and
notice is given to the board, the board shall recommend similar control
of the substance under this article in the board's report to the general
assembly, unless the board objects to inclusion or rescheduling. In that
case, the board shall publish the reasons for objection and afford all
interested parties an opportunity to be heard.

Instrument

Synthetic drug (opening of subdivision (1)); controlled substance analog; Schedule I synthetic drugs

Source

https://iga.in.gov/ic/2026/Title_35.html

Retrieved

2026-11-08

Fingerprint

7b7540f88fd4db94

Sec. 321. "Synthetic drug" means the following:
(1) A substance containing one (1) or more of the following
chemical compounds, including an analog of the compound:

IC 35-48-1.1-8“Controlled substance analog” Sec. 8. (a) “Controlled substance analog” means a
substance that, due to its chemical structure and potential for abuse or
misuse, meets the following criteria:
(1) The substance is substantially similar to a controlled substance
classified under IC 35-48-2.
(2) The substance has a narcotic, stimulant, depressant, or
hallucinogenic effect on the central nervous system or is
represented or intended to have a narcotic, stimulant, depressant,
or hallucinogenic effect on the central nervous system
substantially similar to or greater than that of a controlled
substance classified under IC 35-48-2.
(b) The definition set forth in subsection (a) does not include:
(1) a controlled substance;
(2) a legend drug;
(3) a substance for which there is an approved new drug
application;
(4) any compound, mixture, or preparation that contains any
controlled substance, that is not for administration to a human
being or an animal, and that is packaged in a form or
concentration, or with adulterants or denaturants, such that as
packaged it does not present any significant potential for abuse;
(5) a substance to which an investigational exemption applies
under Section 505 of the federal Food, Drug and Cosmetic Act
(chapter 675, 52 Stat. 1052 (21 U.S.C. 355)), but only to the
extent that conduct with respect to the substance is pursuant to the
exemption; or
(6) low THC hemp extract.
(c) For purposes of subsection (a), “substantially similar”, as it
applies to the chemical structure of a substance, means that the
chemical structure of the substance, when compared to the structure of
a controlled substance, has a single difference in the structural formula
that substitutes one (1) atom or functional group for another, including:
(1) one (1) halogen for another halogen;
(2) one (1) hydrogen for a halogen;
(3) one (1) halogen for a hydrogen; or
(4) an alkyl group added or deleted:
(A) as a side chain to or from a molecule; or
(B) from a side chain of a molecule.
As added by P.L.186-2025, SEC.249.

(g) Synthetic drugs as defined in IC 35-31.5-2-321.

Instrument

Indiana synthetic-drug list (no isomer clause) + hallucinogen isomer definition (optical/positional/geometric)

Source

https://law.justia.com/codes/indiana/title-35/article-31-5/chapter-2/section-35-31-5-2-321/

Retrieved

2026-07-06

Fingerprint

de799d5f56f7bf16

IC 35-31.5-2-321 ("Synthetic drug"), subsection (1) - where mitragynine is listed:
"(1) A substance containing one (1) or more of the following chemical compounds, including an analog of the compound:"
Entries (bare names, no isomer/salt clause):
"7-hydroxymitragynine."
“Mitragynine.”

IC 35-48-2-4(g) (Schedule I hook - NO isomer clause):
"(g) Synthetic drugs as defined in IC 35-31.5-2-321."

IC 35-48-2-4(d) (Hallucinogenic substances - isomer clause, shown for contrast; does NOT govern the (g) synthetic-drug list):
"...their salts, isomers, and salts of isomers whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of this subsection only, the term \“isomer\” includes the optical, position, and geometric isomers)"

IC 35-48-1-17.4 (former general definition of "isomer"): REPEALED effective July 1, 2025 (P.L.186-2025, SEC.248).